Pearl and Patterson Dental Canada announced a collaboration to expand access to Pearl’s Second Opinion AI disease detection capabilities within the Canadian dental market. Pearl’s real-time pathology detection AI software, Second Opinion, assists dentists in their radiologic evaluation and case presentation of dental conditions commonly found in dental x-rays, including caries, bone loss, calculus, and more. The technology, which received its Medical Device Establishment License from Health Canada in 2021, enables dentists to read patient x-rays more accurately and efficiently, enhancing their clinical performance and patient communication.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDCO:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of July 15, 2024
- Patterson Dental selects Weave as patent engagement platform
- Patterson Companies price target lowered to $29 from $30 at JPMorgan
- Patterson Companies price target lowered to $28 from $30 at Morgan Stanley
- Patterson Companies price target lowered to $31 from $32 at BofA
Questions or Comments about the article? Write to editor@tipranks.com